Rafferty Asset Management
RCUS icon

Rafferty Asset Management’s Arcus Biosciences RCUS Stock Holding History

Rafferty Asset Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.49M Buy
115,134
+22,205
+24% +$480K 0.01% 563
2025
Q4 		$2.21M Buy
92,929
+23,280
+33% +$475K 0.01% 625
2025
Q3 		$947K Sell
69,649
-29,041
-29% -$302K ﹤0.01% 804
2025
Q2 		$803K Sell
98,690
-13,636
-12% -$116K ﹤0.01% 797
2025
Q1 		$882K Buy
112,326
+34,644
+45% +$402K ﹤0.01% 765
2024
Q4 		$1.16M Sell
77,682
-6,512
-8% -$106K ﹤0.01% 763
2024
Q3 		$1.29M Sell
84,194
-11,598
-12% -$183K ﹤0.01% 742
2024
Q2 		$1.46M Sell
95,792
-243,875
-72% -$3.94M 0.01% 726
2024
Q1 		$6.41M Buy
339,667
+88,263
+35% +$1.53M 0.02% 409
2023
Q4 		$4.8M Sell
251,404
-41,304
-14% -$660K 0.02% 450
2023
Q3 		$5.25M Sell
292,708
-7,404
-2% -$149K 0.03% 377
2023
Q2 		$6.1M Sell
300,112
-110,880
-27% -$2.11M 0.03% 370
2023
Q1 		$7.5M Buy
410,992
+215,967
+111% +$4.13M 0.05% 262
2022
Q4 		$4.03M Sell
195,025
-33,616
-15% -$925K 0.03% 423
2022
Q3 		$5.98M Buy
228,641
+73,585
+47% +$1.95M 0.06% 293
2022
Q2 		$3.93M Sell
155,056
-6,498
-4% -$159K 0.04% 335
2022
Q1 		$5.1M Buy
161,554
+35,236
+28% +$1.18M 0.03% 388
2021
Q4 		$5.11M Buy
126,318
+43,988
+53% +$1.71M 0.03% 383
2021
Q3 		$2.87M Sell
82,330
-22,469
-21% -$699K 0.02% 507
2021
Q2 		$2.88M Buy
104,799
+13,397
+15% +$383K 0.02% 513
2021
Q1 		$2.57M Buy
91,402
+76,742
+523% +$2.67M 0.02% 562
2020
Q4 		$381K Sell
14,660
-55,687
-79% -$1.35M ﹤0.01% 749
2020
Q3 		$1.21M Buy
70,347
+54,521
+345% +$1.22M 0.01% 553
2020
Q2 		$392K Buy
+15,826
New +$427K 0.01% 768

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Rafferty Asset Management's RCUS Position: Q1 2026 in Review

Rafferty Asset Management increased its Arcus Biosciences (RCUS) stake by 24% in Q1 2026, buying an estimated $480K and bringing the position to 115,134 shares worth $2.49M. The position accounts for 0.01% of the portfolio, ranked #563.

Rafferty Asset Management first reported a position in RCUS in Q2 2020 and has held it in 24 quarters since. The position peaked at $7.5M in Q1 2023. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Rafferty Asset Management held 115,134 shares of Arcus Biosciences worth $2.49M as of Q1 2026.
  • Rafferty Asset Management bought 22,205 Arcus Biosciences shares in Q1 2026, an estimated $480K.
  • Arcus Biosciences made up 0.01% of Rafferty Asset Management's portfolio in Q1 2026, its #563 holding.
  • Rafferty Asset Management first reported a position in Arcus Biosciences in Q2 2020 and has held it in 24 quarters since.
  • Rafferty Asset Management's Arcus Biosciences position peaked at $7.5M in Q1 2023.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.